tbuckley/cabot-search huggingface dataset:
A multi-marker QPCR panel for the detection of circulating tumor cells predicts survival in breast cancer patients.
Authors: TJ Molloy, AJ Bosma, LO Baumbusch, E Borgen, LJ van't Veer, B Naume
Journal: Cancer Research (2009)

Abstract Abstract #305 The detection of circulating tumor cells (CTCs) in the blood of cancer patients is a promising tool for risk stratification, treatment tailoring, and monitoring of the disease state. We previously developed a QPCR-based detection platform for the semi-quantitation of circulating tumor cells in the peripheral blood of breast cancer patients. This CTC assay combines gene expression data from 4 tumor marker genes into a single score using a quadratic discriminant analysis, and is optimized such that positivity indicates tumor cell presence, and negativity indicates tumor cell absence. An initial cohort of metastatic patients demonstrated that score positivity was correlated to a significantly shorter time to disease progression.&amp;#x2028; The current study aimed to validate these results by using the CTC assay in an independent, retrospective patient series consisting of 111 non-metastatic stage I-III breast cancer patients (median followup 7.3 years), 16 metastatic breast cancer patients, and 28 healthy controls. Assay score positivity was observed in 14 out of 16 (88%) metastatic patients, 16 out of 111 (14%) non-metastatic stage I-III patients, and 0 out of 28 (0%) healthy female controls.&amp;#x2028; In the early stage patient group, a positive CTC score was correlated to significantly poorer relapse-free survival (HR = 3.6, 95% CI = 1.7-7.9, p &amp;lt; 0.01) and overall survival (HR = 3.2, 95% CI = 1.6-6.1, p &amp;lt; 0.01). The assay was particularly powerful in patients with no lymph node metastases at time of diagnosis (relapse-free survival HR = 13.0, 95%CI = 3.0-55.7, p &amp;lt; 0.01, overall survival HR = 6.3, 95% CI = 1.9-21.1, p &amp;lt; 0.01). This platform compared very favorably to the traditional immunohistochemistry-based assay for disseminated tumor cell detection in bone marrow utilizing pan-anticytokeratin staining (AE1/AE3), which was not a significant predictor of survival in this patient group (HR = 1.3, 95% CI = 0.6-2.4, p = 0.49). In multivariate analyses, our CTC assay was a significant, independent predictor of overall survival.&amp;#x2028; Work is currently ongoing to expand the study to include an additional 500-600 patients which should serve as a robust validation of the assay. This CTC detection platform represents an objective assay with both high specificity and prognostic power, and could be an effective clinical tool for outcome prediction in breast cancer patients.&amp;#x2028; This work was supported by the Sixth Framework Program of the European Commission as part of the international DISMAL collaboration for research into disseminated epithelial malignancies. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 305.
Abstract IA-14: Molecular alterations that predict premalignancy in breast cancer
Authors: Thea D. Tlsty
Journal: Cancer Research (2009)

Abstract Approximately 15–30% of women diagnosed with ductal carcinoma in situ (DCIS) develop a subsequent tumor event within 10 years after surgical lumpectomy. To date, little is known about the molecular pathways that confer this differential risk for developing subsequent disease. Since DCIS is non-obligate precursor of invasive carcinoma, the majority of DCIS lesions are not associated with subsequent invasive tumors. Likely, many women diagnosed with DCIS who opt for surgery, with or without adjuvant treatment, are being overtreated. Identification of characteristics of DCIS that predict subsequent tumor development would advance our understanding of breast cancer and allow us to stratify a woman's individual risk for subsequent invasive tumors and avoid over- and undertreatment of women with DCIS. To address this clinical problem, we have recently identified biomarkers in DCIS biopsies that accurately predict future formation of tumors, years before it actually occurs. The overexpression of biological markers of stress activation, p16 and COX-2, reflect two biologically different processes that predict women with a better or worse prognosis. In the absence of proliferation, expression of these markers indicates activation of a senescence response and a low probability of tumor formation. In the presence of proliferation, these markers indicate abrogation of the pRb tumor suppressor pathway and are associated with a high likelihood of future tumor formation. We initially tested these markers in a pilot set of DCIS samples (32 cases and 38 controls) obtained from an extensively annotated population-based cohort of women diagnosed with DCIS, treated by lumpectomy alone, and followed for twenty years. These markers identified a highly aggressive subtype of DCIS that shares characteristics with basal-like invasive tumors. We have extended these studies to a larger retrospective cohort, 162 samples from the DCIS cohort (75 cases and 87 controls) and find that the prediction markers faithfully identify women at high and low risk for future tumor formation. Independent validation in a large retrospective cohort is ongoing. The finding that DCIS lesions with basal-like molecular characteristics have an increased risk of developing subsequent cancers suggest this phenotype can be assayed far in advance of the development of invasive disease and present clinical opportunities. Citation Information: Cancer Res 2009;69(23 Suppl):IA-14.
Eye tracking impairment in clinically identified patients with schizotypal personality disorder
Authors: L J Siever, R Keefe, D P Bernstein, E F Coccaro, H M Klar, Z Zemishlany, A E Peterson, M Davidson, T Mahon, T Horvath
Journal: American Journal of Psychiatry (1990)

Eye tracking accuracy, which has been found to be impaired in schizophrenic patients and their relatives, was assessed in 26 patients with schizotypal personality disorder, 17 control subjects with other non-schizophrenia-related personality disorders, 29 normal control subjects, and 44 schizophrenic patients. Both schizotypal and schizophrenic patients, but not control subjects with other personality disorders, demonstrated significantly more impaired tracking than the normal control subjects. These results suggest that patients with clinically defined schizotypal personality disorder may be biologically related to schizophrenic patients as part of a spectrum of schizophrenia-related disorders.
Abstract 5072: Protein signatures associated with dysplasia of ulcerative colitis
Authors: Sheng Pan, David Crispin, Damon May, Mary P. Bronner, Lisa A. Lai, David M. Hockenbery, Martin McIntosh, Teresa A. Brentnall, Ru Chen
Journal: Cancer Research (2011)

Abstract Ulcerative colitis (UC) is an inflammatory bowel disease affecting approximately half a million patients in the United States. Patients with extensive UC of more than eight years duration have an increased risk of colorectal cancer, approximating 0.5-1% per year of colitis. There are major challenges with UC cancer surveillance. Unlike sporadic colon cancer, dysplasia or cancer in UC frequently occurs in benign-appearing colonic mucosa of UC patients without evidence of a polyp. Therefore, an objective molecular biomarker of dysplasia would aid the clinical management of cancer risk in UC patients. We apply a novel, highly sensitive quantitative proteomics approach combining with cutting-edge bioinformatics to develop protein signatures for detecting the neoplastic dysplasia presented in the normal-appearing (i.e., non-dysplastic) colon and rectum for prediction of cancer risk of UC patients. A list of dysregulated proteins potentially associated with colon cancer was identified using large-scale quantitative global protein profiling. Functional analysis was performed to explore the mechanisms that may underlie UC neoplastic progression. Mitochondrial proteins, cytoskeletal proteins, RAS superfamily, proteins relating to apoptosis and metabolism are the important protein groups or pathways differentially expressed in the non-dysplastic and dysplastic tissues of UC progressors, suggesting their importance in UC neoplastic progression. The resultant protein candidates have been ranked and are being rigorously validated using complementary methods, including immunohistochemistry and emerging technology of targeted quantitative proteomics. A molecular signature combining multiple proteins has displayed a statistically significant difference in distinguishing patients with dysplasia/cancer from patients without dysplasia/cancer. Protein biomarker candidates identified in this study may potentially be useful in predictive risk assessment and/or early diagnosis of inflammatory bowel disease associated colorectal cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5072. doi:10.1158/1538-7445.AM2011-5072
Evaluation of Data From Longterm Rodent Studies
Authors: S. S. YOUNG
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Evaluation of Data From Longterm Rodent Studies Get access S. STANLEY YOUNG S. STANLEY YOUNG Glaxo Inc.Research Triangle Park, North Carolina 27709 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 1, 2 March 1988, Pages 3–4, https://doi.org/10.1093/jnci/80.1.3 Published: 02 March 1988
CARDIAC REHABILITATION FOLLOWING ACUTE MYOCARDIAL INFARCTION, TRENDS IN REFERRAL OVER THE PAST DECADE, PREDICTORS OF REFERRAL, AND ONE-YEAR MORTALITY OUTCOME IN A MULTICENTER NATIONAL REGISTRY BETWEEN 2006-2013
Authors: Avi Sabbag, Fernando Chernomordik, Ilan Goldenberg, Shlomi Matetzky, Robert Klempfner
Journal: Journal of the American College of Cardiology (2016)
All Patients with Acute Nonlymphocytic Leukemia May Have a Chromosomal Defect
Authors: Jorge J. Yunis, Clara D. Bloomfield, Kathy Ensrud
Journal: New England Journal of Medicine (1981)

Previous studies of banded marrow chromosomes suggest that half the patients with acute nonlymphocytic leukemia (ANLL) have normal karyotypes. To determine whether high-resolution chromosome analysis could detect additional abnormalities, we studied marrow from 26 patients with ANLL, using methotrexate cell synchronization as well as a direct technique. In 24 patients, including 18 who were untreated, adequate mitoses were obtained. All demonstrated clonal chromosomal abnormalities, which involved a balanced translocation in 11 cases, a complete or partial monosomy in 10, and a trisomy in six. Previously reported recurring defects in ANLL were identified, including t(15;17) in two cases, -7 in two cases, and +8 in three cases. In addition, a new specific abnormality involving band 11q23 was noted in one patient with acute monocytic leukemia and in two with myelomonocytic leukemia. Our results suggest that most, if not all, patients with ANLL have chromosomal changes, and that our new technique may allow more precise identification of subtypes of ANLL with characteristic clinical and hematologic features. (N Engl J Med. 1981; 305:135–9)
Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28
Authors: Eleftherios P Mamounas, Gong Tang, Soonmyung Paik, Frederick L Baehner, Qing Liu, Jong-Hyeon Jeong, Seong-Rim Kim, Steven M Butler, Farid Jamshidian, Diana B Cherbavaz, Amy P Sing, Steven Shak, Thomas B Julian, Barry C Lembersky, D Lawrence Wickerham, Joseph P Costantino, Norman Wolmark
Journal: Cancer Research (2012)

Abstract Withdrawn by Author Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-01.
Clinical Breast Examination and Breast Cancer Screening Guideline—Reply
Authors: Kevin C. Oeffinger, Elizabeth T. H. Fontham, Richard C. Wender
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0172 Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and spondyloarthropathies. results from the monitornet database:
Authors: R. Caporali, C.A. Scirè, M. Todoerti, M. Galeazzi, G. Valesini, P. Sfriso, R. Tirri, M. Filippini, P. Sarzi-Puttini, R. Pellerito, G. Delsante, A. Mathieu, L. Sinigaglia, F. Salaffi, G. Minisola, C. Montecucco, S. Todesco
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Pharmaco-epidemiological studies on TNF-inhibitors (TNF-I) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) are providing useful data about effectiveness and safety in clinical practice. <h3>Objectives</h3> To compare drug survival in RA and SpA according to TNF-I drug using data from a multicentre Italian cohort study. <h3>Methods</h3> The patients were selected from the Monitornet database, a prospective cohort study to monitor the long-term safety of biologic therapy involving 27 rheumatology centres across Italy, supported by the Italian regulatory agency AIFA. For the purpose of these analyses we included RA or SpA patients, who started a first course infliximab (INF), etanercept (ETA) or adalimumab (ADA). Drug survival was primarily defined from start until first discontinuation (overall drug survival) and secondarily due to ineffectiveness or adverse events (AEs). A first set of analyses assessed the relationship between diagnosis and drug survival using RA as reference category, adjusting for age, gender and comorbidities. A second set of analyses stratified by diagnosis explored the relationship between TNF-I and drug survival using INF as reference category, adjusting for age, gender, comorbidities, disease duration, previous DMARDs, calendar, baseline CRP, disease activity (DAS28 or BASDAI) and severity (HAQ score or BASFI). Drug survival was analyzed using Cox proportional hazards models. Results are presented as hazard ratios (HR) and 95% confidence intervals (CI). <h3>Results</h3> 1992 RA patients (79.8% women, mean age 55.5 yrs (SD 12.3), mean disease duration 9.6 yrs (SD 8.0), mean baseline DA28 4.4 (SD 1.9), baseline HAQ 1.4 (SD 0.7), median number of previous DMARDs 2 (IQR 1-3) and 993 SpA patients (55.2% men, mean age 49.6 yrs (SD 12.5), mean disease duration 6.9 yrs (7.5), mean baseline BASDAI 4.7 (SD 2.4), mean baseline BASFI 4.6 (SD 2.5) were included in the analyses. 44.2% RA patients started ETA, 21.4% INF, 34.4% ADA, while 45.8% SpA patients ETA, 22.3% INF, 31.9% ADA. Using RA as reference, SpA patients showed a lower drug discontinuation (HR 0.92 [95%CI 0.87, 0.99]), due to a lower withdrawal for inefficacy (HR 0.90 [95%CI 0.82, 0.99]). Both in RA and in SpA, compared to INF, ETA showed a slightly better survival on treatment, also due to lower discontinuation for inefficacy (see table). <h3>Conclusions</h3> These data support a better survival on treatment for SpA over RA and for ETA as compared with INF, mainly due to lower discontinuation for ineffectiveness rather than for AEs. <h3>Disclosure of Interest</h3> None Declared
First-Degree Relatives of Patients with Type I Diabetes Mellitus
Authors: S. Srikanta, Om P. Ganda, Albert Rabizadeh, J. Stuart Soeldner, George S. Eisenbarth
Journal: New England Journal of Medicine (1985)

In a prospective study to evaluate the prevalence and predictive potential of circulating islet-cell antibodies, we have screened 1723 "normal" first-degree relatives (parents, siblings, and offspring) of patients with insulin-dependent diabetes mellitus. The prevalence of islet-cell antibodies on initial screening was 0.9 per cent (16 of 1723). Over a maximal follow-up period of two years, insulin-dependent diabetes mellitus developed in 2 of 16 relatives with islet-cell antibodies and in 1 of 1707 without antibodies. In addition, 6 of 12 nondiabetic relatives with islet-cell antibodies had abnormally low insulin responses — below the third percentile in 6 and below the first percentile in 4 — on their initial intravenous glucose challenge. Thus, prospective islet-cell antibody screening of high-risk first-degree relatives, in combination with intravenous glucose-tolerance testing, is capable of identifying immunologically abnormal persons with profoundly diminished beta-cell function, who are presumably at increased risk of insulin-dependent diabetes mellitus. (N Engl J Med 1985; 313:461–4.)
Glucose in the ICU — Evidence, Guidelines, and Outcomes
Authors: Brian P. Kavanagh
Journal: New England Journal of Medicine (2012)

Just over a decade ago, a single-center Belgian study showed that normalization of blood glucose in critically ill patients lowered hospital mortality by more than 30%.1 Although subsequent studies were unable to reproduce these findings, the appeal of such a straightforward intervention was too great to resist: guidelines from professional organizations2,3 were published, and editorial commentary4 highlighted initiatives by the Institute for Healthcare Improvement, the Joint Commission on Accreditation of Healthcare Organizations, and the Volunteer Hospital Association that incorporated tight glucose control as a standard. Indeed, the prestigious Codman Award of the Joint Commission was presented in 2004 for . . .
Insertion of a self-expanding metal stent for a stomal stenosis
Authors: W. Kim, C.-I. Kwon, J. Kim, C. Lee
Journal: Endoscopy (2012)

Stenosis is one of the major complications of a gastrointestinal stoma, yet its treatment is not well established [1] [2] [3]. We report a case of stomal stenosis that improved after insertion of a temporary self-expanding metal stent (SEMS). A 61-year-old woman presented with a stoma that had been malfunctioning for 2 months. She had been diagnosed with recurrent cervical cancer and admitted 7 months previously because of life-threatening rectal bleeding. The bleeding had come from a branch of the internal iliac artery and had passed through a tract formed between the rectum and the recurrent cervical cancer by a necrotic abscess. She had been treated with emergent transarterial embolization and coiling and had subsequently undergone a T-loop transverse colostomy with stoma formation to prevent stool passing into the tract. For the past 2 months, however, her stools had been mainly passing out through her urethra and anus, rather than through the stoma.
COMPARACIÓN DE DOS TÉCNICAS DE SUTURA ENDOSCÓPICA PARA EL CIERRE DEL ORIFICIO DE ACCESO PERITONEAL
Authors: JR Armengol Miró, J Dot Bach, M Abu-Suboh Abadia, J Armengol Bertroli, A Benages Curell, M Masachs Peracaula, X Zhang, JC Salord Oses, L Rivero, D Castillo, SV Kantsevoy
Journal: Endoscopy (2012)

Introducción: En las intervenciones de NOTES, el Cierre endoscópico de la incisión de la pared transgástrica creado para acceder a cavidad peritoneal sigue siendo problemática. Se han usado diferentes técnicas, (cierre con clips endoscópicos, T-bar, dispositivos de grapado, etc) que no han alcanzado una calidad de cierre similar a la sutura quirúrgica. Objetivo: Comparar los resultados clínicos e histológicos de un nuevo dispositivo de sutura endoscópico (Overstitch ®, Endosurgery Apolo, Inc., Austin, TX) utilizando sutura continua o bien puntos separados, en un estudio controlado, prospectivo y aleatorizado, en modelo porcino. Método: Se realiza acceso estándar a la cavidad peritoneal, utilizando la técnica de la pared gástrica con dilatación posterior con balón de 20mm (Boston Scientific, Natick, MA). Después de realizar una peritoneoscopia, se retiró el endoscopio al estómago y los animales fueron asignados al azar a cierre de la incisión gástrica con línea de sutura continua (4–6 punciones sucesivas de cada sitio de la incisión de la pared gástrica, con la consiguiente contracción y apretando la línea de sutura) o bien línea de sutura interrumpida (un pinchazo en cada sitio de la incisión con cincha posterior). Una vez terminada la incisión, se insufló el estomago con dióxido de carbono y se realizó test de fugas de aire para demostrar la hermeticidad del cierre. Todos los animales sobrevivieron 14días, y tras este periodo fueron sacrificados y se practicó estudio. Resultados: Se completaron con éxito 16 experimentos (8 en cada grupo). La sutura de la incisión de la pared gástrica se logro con facilidad y se comprobó la hermeticidad del cierre en todos los animales. El tiempo medio para completar la línea continua de sutura fue 7,43 +/–2,59 minutos, mientras que el tiempo medio para completar el cierre con sutura interrumpida fue 10,49 +/–3,8 minutos. No hubo complicaciones post-procedimiento en ninguno de los animales. El examen post-mortem no reveló signos de complicaciones intraperitoneales de peritonitis o de otro tipo en ninguno de los grupos. El examen histológico mostró cicatrización transmural completa con buena oposición de las capas de la pared del estomago en todos los animales. Conclusión: El dispositivo de sutura endoscópica Overstich, es un sistema fácil, fiable, y de manejo sencillo. La sutura continua es mas rápida, pero los resultados clínicos e histológicos fueron igual de exitosos en ambos grupos.
WHICH VITAMIN D METABOLITE BEST PREDICTS FUTURE ADVERSE CARDIOVASCULAR EVENTS? RESULTS FROM THE INTERMOUNTAIN HEART COLLABORATIVE STUDY
Authors: Heidi Thomas May, Oxana Galenko, John Carlquist, Lindell K. Weaver, Stacey Knight, Tyler Barker, J. Muhlestein
Journal: Journal of the American College of Cardiology (2016)